Ophthalmology

Lai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor.

Avant Technologies and Ainnova Tech refine clinical trial protocol for Vision AI platform, aiming for FDA 510(k) approval to enhance diabetic retinopathy detection.

Clearside Biomedical secures Health Canada approval for Xipere, while exploring strategic options to enhance its suprachoroidal delivery platform and pipeline.

Andrew G. Lee, MD, shares essential insights on neuro-ophthalmology for retina specialists, emphasizing diagnosis techniques and collaboration with neuro-ops.

Re-Vana Therapeutics and Boehringer Ingelheim forge a $1 billion partnership to develop innovative extended-release therapies for eye diseases, enhancing patient care.

Mucormycosis emerges as a critical concern in diabetic patients with sudden vision loss, highlighting the need for prompt diagnosis and treatment.

New tariffs threaten the optical industry, prompting urgent reevaluation of sourcing strategies and pricing as deadlines approach for affected countries.

A recent study reveals cannabis use may lower the risk of proliferative vitreoretinopathy after retinal detachment repair, suggesting potential therapeutic benefits.

Patients express mixed feelings about AI in healthcare, favoring its use for documentation and administrative tasks while demanding transparency and safety standards.

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants in the MERTK gene.

The report highlights clinical successes, innovation, research, and patient outcomes.

In a recent study, the researchers suggested that targeting the circuits responsible for visual acuity may be necessary in achieving optimal recovery of visual function and could aid in the development of vision restoration therapies.

Gore recently launched its silicone-free GORE IMPROJECT Plunger for 0.5-mL pre-filled syringes for the delivery of ophthalmic drugs.

Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings suggest that neurologic diseases impact ocular health.

The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.

The cross sector initiative that intends to drive a shift from reactive to proactive health care by leveraging ocular data through the means of oculomics.

The system was taught quality standards by being fed more than 1400 images from different parts of the retina taken by adaptive-optics ophthalmoscopy.

The recent study details the diagnostic value of a multimodal model utilizing both types of biomarkers when compared to unimodal models.

DREAM is an acronym for deep imaging depth, rapid sweeping speed, extensive scan range, accurate results, and multimodal imaging capabilities.

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease and diabetic macular edema (DME).

Post hoc analysis of GATHER1 and GATHER2 showed that reduced EZ-RPE central subfield thickness is a strong predictor of greater future vision loss.

New research reveals subretinal drusenoid deposits as potential indicators of serious heart disease, highlighting the need for ophthalmologists to screen patients effectively.

Neurotech partners with Cencora for the U.S. launch of ENCELTO, the first FDA-approved treatment for MacTel, enhancing patient access and support.

A large international study reported a genetic link between schizophrenia and retinal status.

A two-way foot bridge between eye care and mental health.

Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis.

Industry leaders discuss the impact of rising tariffs on vision care costs, advocating for policy changes to ensure affordable access to essential eyewear.

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”

Phase I/II safety and efficacy study currently enrolling.